Cycle Drug Patent Portfolio
Cycle owns 2 orange book drugs protected by 4 US patents Given below is the list of Cycle's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10555902 | Stable fingolimod dosage forms | 19 Jan, 2036 | Active |
| US10925829 | Stable solid fingolimod dosage forms | 19 Jan, 2036 | Active |
| US9925138 | Stable solid fingolimod dosage forms | 19 Jan, 2036 | Active |
| US10328029 | Pharmaceutical composition | 05 Jan, 2035 | Active |
Latest Legal Activities on Cycle's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Cycle.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 05 Jul, 2023 | US10555902 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 01 Dec, 2022 | US10328029 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 25 Jun, 2021 | US9925138 |
|
Recordation of Patent Grant Mailed
Critical
| 23 Feb, 2021 | US10925829 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 23 Feb, 2021 | US10925829 |
|
Email Notification
Critical
| 04 Feb, 2021 | US10925829 |
|
Issue Notification Mailed
Critical
| 03 Feb, 2021 | US10925829 |
|
Application Is Considered Ready for Issue
Critical
| 20 Jan, 2021 | US10925829 |
| Dispatch to FDC | 20 Jan, 2021 | US10925829 |
|
Issue Fee Payment Received
Critical
| 19 Jan, 2021 | US10925829 |
|
Issue Fee Payment Verified
Critical
| 19 Jan, 2021 | US10925829 |
|
Email Notification
Critical
| 17 Nov, 2020 | US10328029 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 17 Nov, 2020 | US10328029 |
|
Correspondence Address Change
Critical
| 13 Nov, 2020 | US10328029 |
|
Mail Notice of Allowance
Critical
| 23 Oct, 2020 | US10925829 |
Cycle's Family Patents
Cycle Drug List
Given below is the complete list of Cycle's drugs and the patents protecting them.
1. Nityr
Nityr is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10328029 | Pharmaceutical composition |
05 Jan, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nityr's drug page
2. Tascenso Odt
Tascenso Odt is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10555902 | Stable fingolimod dosage forms |
19 Jan, 2036
(11 years from now)
| Active |
| US10925829 | Stable solid fingolimod dosage forms |
19 Jan, 2036
(11 years from now)
| Active |
| US9925138 | Stable solid fingolimod dosage forms |
19 Jan, 2036
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tascenso Odt's drug page